Members Directory

Reset map/result filters

Showing 29 out of 29 results

  • 123 Old Brompton Rd, Kensington, London SW7, UK
  • Wilmslow Rd, Manchester, Manchester, UK
  • 7 Tavistock Pl, Kings Cross, London WC1H 9SN, UK
  • In response to its growing database of early-stage drug discovery programmes and opportunities, UCL is investing in expertise to implement a strategic plan to integrate and strengthen its drug discovery capabilities, especially in dedicated medicinal chemistry.
    As part of this wider Drug Discovery initiative, the TRO, in partnership with the School of Pharmacy, has established a core medicinal chemistry facility. Populated by experienced, industry-background medicinal chemists, the group is based in the School of Pharmacy’s established laboratories.
    29 Brunswick Square, London WC1N 1AX, UK
  • In April 2015 London Research Institute of Cancer Research UK officially became part of the Francis Crick Institute, a consortium of six of the UK's most successful scientific and academic organisations - the Medical Research Council, Cancer Research UK, the Wellcome Trust, UCL (University College London), Imperial College London and King's College London. Some 1200 scientists will be located in a new purpose-built building in central London by 2016. The Francis Crick Institute is an inter-disciplinary medical research institute. Its work will help understand why disease develops and find new ways to treat, diagnose and prevent illnesses such as cancer, heart disease and stroke, infections, and neurodegenerative diseases.
    215 Euston Road, Kings Cross, London NW1 2BE, UK
  • The Drug Discovery Programme (DDP) has been funded by Cancer Research UK and headed by Martin Drysdale. Our goal is to establish an integrated, industry-standard drug discovery programme to translate basic biology research from the Beatson and other CRUK centres into medicines for the treatment of cancer.
    The Beatson Institute's Research Facilities, which are overseen by Sue Fowler, support all members of the Institute and can also be accessed by other Cancer Research UK-funded scientists within Glasgow, particularly our colleagues within the Institute of Cancer Sciences.
    Garscube Estate, Switchback Road, Bearsden, Glasgow, East Dunbartonshire G61 1BD, UK
  • The Drug Discovery group at the Centre for Cancer Research and Cell Biology (CCRCB) integrates both academic and industrial scientists to facilitate the translation of basic research discoveries into products which can ultimately derive value for patients. The mission of the Drug Discovery group is to identify molecular targets which are relevant to disease and to develop strategies to modulate their function.
    Lisburn Road, Belfast, Belfast BT9 7AE, UK
  • The University of Birmingham is committed to being at the vanguard of academic-led drug discovery and the search for the next generation of therapies that will benefit humankind. Recently, the University of Birmingham has invested nearly three quarters of a million pounds to develop a High-Throughput Screening (HTS) facility. The Birmingham Drug Discovery Facility contains a number of cutting-edge technologies required to enable Birmingham scientists to conduct translational science.
    Birmingham, Birmingham, West Midlands B15, UK
  • CRT has access to its own Discovery Laboratories (CRT-DL), with in-house capabilities including target and cellular biology, assay development, HTS, crystallography, DMPK and medicinal chemistry. CRT-DL has pioneered an innovative operating model which brings together the best minds in industry and academia to work around themed areas of cancer biology.
    Cambridge, Cambridgeshire CB22 3AT, UK
  • The RSF couples High Throughput RNA interference (RNAi) screening and drug repurposing approaches with High Content Imaging (HCI) to translate fundamental cancer research towards new therapies. Collectively, these approaches provide a powerful tool for identifying novel/key players in a system of interest and elucidating novel drug targets and/or drug partners to improve existing cancer therapeutic approaches.
    Garscube Estate, Switchback Road, Bearsden, Glasgow, East Dunbartonshire G61 1BD, UK
  • The Drug Discovery Unit builds upon fundamental biology discoveries made within the CRUK Manchester Institute, the Manchester Cancer Research Centre, The University of Manchester and the wider cancer research community.  Integrating medicinal, computational and synthetic chemistry with in vitro and cellular biology, the centre investigates novel drug discovery targets in an attempt to provide new chemical entities for the treatment of unmet clinical needs in cancer patients.
    550 Wilmslow Road, Manchester, Manchester M20 4BX, UK
  • The Cancer Research UK Cancer Therapeutics Unit is the largest academic cancer drug discovery and development group worldwide. Its 12 research teams cover every aspect of new drug discovery and development, from cell and molecular biology through to chemical synthesis of new agents and their evaluation in clinical trials.
    237 Fulham Road, London SW3 6JB, UK
  • The Drug Discovery Unit is a fully operational, fully integrated drug discovery group working across multiple disease areas. We collaborate with partners to translate world-class biology research into novel drug targets and candidate drugs to address unmet medical need across our two areas of activity, Diseases of the Developing World and Innovative Targets Portfolio.
    Dow Street, Dundee, Dundee City DD1 5EH, UK
  • The National Phenotypic Screening Centre (NPSC) is a new drug discovery venture funded by the Scottish Universities Life Science Alliance (SULSA) based in Dundee and Oxford and working closely with Edinburgh University. Its focus is applying advanced phenotypic approaches to drug discovery for complex human diseases in order to rebalance the current emphasis on target-based screening.
    Dow Street, Dundee, Dundee City DD1 5EH, UK
  • The European Screening Centre, Newhouse is an integrated drug discovery/chemical biology group that provides an array of compound screening and medicinal chemistry capabilities. With skills in biology, chemistry and technologies, it is a key group within the IMI funded European Lead Factory and is located at Biocity Scotland in Lanarkshire. With greater than 150 years of collective experience gained in pharma, biotech and academic environments the scientists have extensive knowledge of translational research and the drug discovery cycle over a wide range of target classes.
    Dow Street, Dundee, Dundee City DD1 5EH, UK
  • The overarching aims of the ECDU are to enhance clinical predictivity of preclinical oncology drug discovery strategies and improve patient stratification and efficacy, by applying an evidence-led translational research platform, incorporating disease relevant models systems, innovative chemical design, quantitative in vitro and in vivo imaging and genomic/proteomic discovery informatics.
    19 Crewe Road South, Edinburgh, Edinburgh EH4 2HY, UK
  • The Scottish Bioscreening Facility originated as a joint SULSA and Wellcome Trust funded initiative to stimulate collaborations and enable large siRNA and compound library screens. The SBF is based around High Content Image Based Screening (HCS) with the GE IN Cell 2000©. This wide-field fluorescence microscopy platform is useful for high throughput image capture and analysis of numerous parameters in a biologically relevant context.
    Sutherland Lane, Glasgow, Glasgow City G12, UK
  • The MCCB group provides a comprehensive and integrated medicinal chemistry, high-throughput screening, and molecular modelling capability for the identification of novel small molecule therapeutics and probes. A primary aim of the group is to pump-prime projects via the provision of suitable resources such that projects are suitable to go forward for major external grant funding involving the MCCB group as a collaborator.
    University of Leeds, Leeds, West Yorkshire LS2 9JT, UK
  • siRNA is a powerful tool that identifies the function of genes by silencing their expression and examining the phenotypic consequences. At the BSTG we primarily perform cell based whole or part-genome siRNA screens to individually silence genes in the human or mouse genome to identify genes that impact on cellular pathways and human disease. To achieve this we develop specific end-point phenotypic assays (based on high content microscopy or fluorimetery) to assess the consequences of knockdown and identify genes associated with the phenotype or disease of interest.
    University of Leeds, Leeds, West Yorkshire LS2 9JT, UK
  • At the University of Leeds we have developed a novel antibody-mimetic technology called Adhiron (commercially known as Affimers) that can mimic the molecular recognition of an antibody but can also be expressed in cells for functional studies. As well as guiding the development of new therapeutic molecules to relevant epitopes on target proteins, the Adhirons can be used as tool reagents for assay development work to rapidly identify competitive binders from both small molecule and peptide ligands screens. Being able to rapidly screen millions of potential binders to identify the few significant leads, Adhiron reduces the cost and time needed to develop a drug and often shows lower toxicity effects than small molecule drugs.
    University of Leeds, Leeds, West Yorkshire LS2 9JT, UK
  • LifeArc is the new name for MRC Technology, a medical research charity with a 25 year legacy of helping scientists and organisations turn their research into treatments and diagnostics for patients. The new name reflects the charity’s purpose: to be the arc or bridge between research and improving patients’ lives. LifeArc is pioneering new ways to turn great science into greater patient impact. It brings together a network of partners to tackle specific diseases and directly funds academic and early stage research. So far, LifeArc’s work has helped to develop four drugs (Keytruda®, Actemra®, Tysabri® and Entyvio®) and a test for antimicrobial resistance. Twitter @lifearc1.
    Lynton House, 7-12 Tavistock Square, Kings Cross, London WC1H 9LT, UK
  • The MRC LMCB at UCL is a Medical Research Council-UCL University Unit and centre for research into fundamental aspects of cell function and their links to human disease. The institute is located in the heart of the Gower Street Campus of UCL and currently houses twenty research groups funded by the MRC, Cancer Research UK, The Welcome Trust and University College London. The screening facility at the LMCB is funded by the MRC and facilitates siRNA, cDNA, CRISPR and small molecule screening in all areas of cell biology and biomedicine.
    University College London, Gower Street, Kings Cross, London WC1E 6BT, UK
  • The Pharmacology & Drug Discovery Research Group brings together a range of experts in many disciplines from across The University of Nottingham. It provides a major contribution to the University’s research in drug discovery.
    Finch Close, Nottingham, Nottinghamshire NG7 2NN, UK
  • The Institute investigates drug target discovery across various diseases drawing on the expertise of the research staff on the Campus, Medical Science Division and wider University capitalizing on existing strengths in genetics and genomic medicine, molecular and cell biology, structural biology, chemistry, pharmacology and medicine. The TDI is generously supported by our core partners, the UK government (HEFCE) and Li Ka Shing, and several University of Oxford contributors including the Nuffield Department of Medicine, Department of Oncology and CRUK, Ludwig Institute for Cancer Research and Cardiovascular Medicine and the BHF.
    Old Road Campus, Oxford, Oxford OX3, UK
  • Based at the University of Sheffield, our facility provides specialist equipment to assist the wider scientific community in carrying out high-throughput RNAi screens with Drosophila cells. We offer either pre-aliquoted whole genome RNAi libraries or sub-libraries of target probes. We support both plate reader assays, high-content microscopy as well as the equipment needed to process these samples in a high-throughput fashion. This can either be used to identify genes involved in disease representing future drug targets, or to identify genes involved in biological processes.
    297 Western Bank, Sheffield, South Yorkshire S10 2TJ, UK
  • The Sheffield Institute for Translational Neuroscience (SITraN) is an essential development in the fight against motor neuron disease and other common neurodegenerative disorders of the motor system. As yet no single institution anywhere in the world has developed the necessary critical mass and facilities to exploit the potential of modern neuroscience, the 'post-genome' era, and exciting developments in biomedical therapeutics with specific focus on this devastating group of illnesses.
    375-385 Glossop Road, Sheffield, South Yorkshire S10 2HQ, UK
  • The Bateson Centre Small Molecule Screening Unit (BSMSU) is a multiuser, cross-disciplinary facility that specialises in drug discovery using a wide range of assays. Predominantly it provides a platform for whole-organism (zebrafish) in vivo screens for researchers that are studying a range of developmental and disease mechanisms. The facility may also be used to identify new potential therapeutic small molecules or test drug toxicities. It supports innovative collaborations with both academic and industrial partners.
    309 Western Bank, Sheffield, South Yorkshire S10 2TJ, UK
  • The Translational Drug Discovery Group (TDDG) was established in 2011 as part of a strategic investment by the University of Sussex in the School of Life Sciences. The group comprises medicinal chemistry and molecular pharmacology laboratories and aims to translate a fundamental understanding of disease processes and molecular targets into novel drugs. Research is currently focussed on Oncology, Neuroscience, Respiratory and Ion channels.
    Biology Road, Falmer, Brighton, The City of Brighton and Hove BN1, UK

- Enter Your Location -
- or -